TScan Therapeutics, Inc.

NasdaqGM:TCRX Stock Report

Market Cap: US$21.7m

TScan Therapeutics Management

Management criteria checks 2/4

TScan Therapeutics' CEO is Gavin MacBeath, appointed in Mar 2023, has a tenure of 3.5 years. total yearly compensation is $2.80M, comprised of 23.7% salary and 76.3% bonuses, including company stock and options. directly owns 0.073% of the company’s shares, worth $15.95K. The average tenure of the management team and the board of directors is 3.6 years and 3.4 years respectively.

Key information

Gavin MacBeath

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage23.74%
CEO tenure3.5yrs
CEO ownership0.07%
Management average tenure3.6yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

Seeking Alpha • Mar 07

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Summary Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barring positive feedback from regulatory authorities, the company hopes to develop TSC-101 for AML, MDS, ALL patients who undergo HSCT in a pivotal study in the 2nd half of 2025. The company is developing multiplex TCR-Ts for treatment of patients with solid tumors, with phase 1 PLEXI-T trial data anticipated in the second half of 2025. Financially stable with $290.1 million in cash, TScan Therapeutics has secured a non-dilutive loan and a $30 million direct offering. Read the full article on Seeking Alpha
Seeking Alpha • Feb 10

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Summary TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism. TCRX's potential approval for TSC-101 could tap a $100-$200 million market, making the current valuation a bargain despite inherent risks. Read the full article on Seeking Alpha
Analysis Article • Nov 06

Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Aug 26

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Summary TScan Therapeutics focuses on TCR-T therapies for cancer and autoimmune diseases, leveraging its ImmunoBank and proprietary ReceptorScan platform. TCRX’s pipeline is in the early clinical stages, with multiple near-term catalysts, including promising regulatory designations and potential partnerships. The company’s leading candidates, TSC-100 and TSC-101, target AML, MDS, and ALL, with FDA RMAT designation potentially expediting approval. TCRX seems well-capitalized, with a strong balance sheet and a cash runway of 4 years. It also appears undervalued relative to its peers. Despite its early-stage research, I believe TCRX’s innovative technology and near-term catalysts make it a speculative "buy." Read the full article on Seeking Alpha
Analysis Article • Mar 23

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

It's not a stretch to say that TScan Therapeutics, Inc.'s ( NASDAQ:TCRX ) price-to-sales (or "P/S") ratio of 18.2x...
Analysis Article • Feb 17

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 11

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

TScan Therapeutics, Inc. ( NASDAQ:TCRX ) just released its latest yearly report and things are not looking great...
Seeking Alpha • Aug 10

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

TScan Therapeutics press release (NASDAQ:TCRX): Q2 GAAP EPS of -$0.63 beats by $0.13. Revenue of $4.05M (+42.6% Y/Y) beats by $1.05M.
Seeking Alpha • Jul 07

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

TScan Therapeutics (NASDAQ:TCRX) has appointed Dr. Debora Barton,  as Chief Medical Officer.  Most recently, Dr. Barton was the Chief Medical Officer at Carisma Therapeutics.  In May, TScan got FDA nod to start trial of TSC-101 in blood cancer patients undergoing cell transplant.
Analysis Article • May 22

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 17

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 18

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

CEO Compensation Analysis

How has Gavin MacBeath's remuneration changed compared to TScan Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$118m

Mar 31 2026n/an/a

-US$124m

Dec 31 2025US$3mUS$665k

-US$130m

Sep 30 2025n/an/a

-US$143m

Jun 30 2025n/an/a

-US$137m

Mar 31 2025n/an/a

-US$131m

Dec 31 2024US$2mUS$620k

-US$127m

Sep 30 2024n/an/a

-US$111m

Jun 30 2024n/an/a

-US$104m

Mar 31 2024n/an/a

-US$97m

Dec 31 2023US$3mUS$545k

-US$89m

Sep 30 2023n/an/a

-US$88m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$1mUS$450k

-US$66m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$1mUS$400k

-US$49m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$533kUS$350k

-US$26m

Compensation vs Market: Gavin's total compensation ($USD2.80M) is above average for companies of similar size in the US market ($USD652.98K).

Compensation vs Earnings: Gavin's compensation has increased whilst the company is unprofitable.

CEO

Gavin MacBeath (56 yo)

3.5yrs
Tenure
US$2,801,450
Compensation

Dr. Gavin MacBeath, Ph D., serves as CEO & Director of TScan Therapeutics, Inc. from May 24, 2023 and serves as its Principal Financial Officer & Principal Accounting Officer since September 2, 2026 and se...

Leadership Team

NamePositionTenureCompensationOwnership
Gavin MacBeath
CEO, Principal Financial Officer3.5yrsUS$2.80m0.073%
$ 15.9k
Stephen Elledge
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Tomasz Kula
Co-Founder & Member of Advisory Boardno datano datano data
Zoran Zdraveski
Chief Legal & Strategy Officer and Company Secretary5yrsUS$1.58mno data
Ann Hargraves
Chief Human Resources Officer6.7yrsno datano data
Shrikanta Chattopadhyay
Senior VP & Head of Translational Medicine3.7yrsno datano data
Jim Murray
Chief Development Operations Officer2.6yrsno datano data
Cagan Gurer
Senior Vice President of Discovery2.6yrsno datano data
3.6yrs
Average Tenure

Experienced Management: TCRX's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gavin MacBeath
CEO, Principal Financial Officer3.3yrsUS$2.80m0.073%
$ 15.9k
Stephen Elledge
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Tomasz Kula
Co-Founder & Member of Advisory Boardno datano datano data
Malcolm Brenner
Member of Advisory Boardno datano datano data
Stephen Biggar
Independent Chair of the Board5.5yrsUS$162.23k0%
$ 0
Katina Dorton
Independent Director5.5yrsUS$139.11k0%
$ 0
Garry Nicholson
Independent Director2.3yrsUS$125.36k0%
$ 0
Barbara Klencke
Independent Director3.4yrsUS$145.78k0.10%
$ 22.4k
Kai Wucherpfennig
Member of Advisory Boardno datano datano data
Robert Woods
Independent Director2.8yrsUS$125.27k0%
$ 0
Gabriela Gruia
Independent Director5.3yrsUS$129.12k0%
$ 0
3.4yrs
Average Tenure
68.5yo
Average Age

Experienced Board: TCRX's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 05:00
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TScan Therapeutics, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.
Christopher HowertonJefferies LLC